Heart Valve Replacement Articles & Analysis
12 news found
Phillip Chan, Chief Executive Officer of CytoSorbents, stated, “Today, infective endocarditis makes up a minor part of our overall usage and revenue in cardiac surgery and we believe that CytoSorb will continue to be used in selected infective endocarditis populations. For example, prosthetic heart valve endocarditis is associated with very high mortality ...
MUNICH, Germany – February 4th, 2020: In the future, novel polymers should make it possible to individually manufacture artificial elastic tissue replacements for pericardium, heart valves or blood vessels. In the PolyKARD project, biomimetic polymers are being developed that can imitate the mechanical properties of pericardial tissue. ...
Neuchâtel, Switzerland, February 22, 2019 – Novostia announces that it raised CHF 6.5 million from private investors to advance its disruptive aortic and mitral heart valve to clinical trials. Heart valve diseases affect more than 100 million people worldwide. Every year hundreds of thousands of patients undergo a ...
Colibri Heart Valve LLC, a privately held emerging medical device company, today announced that results from the company’s international, single-arm, open-label early feasibility study (EFS) of the Colibri transcatheter aortic valve implantation (TAVI) system will be presented at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) ...
This proprietary TAVI system features a replacement heart valve pre-mounted and pre-crimped on a balloon delivery catheter, pre-loaded into a low-profile access sheath and sterilized, ready-for-use from package to patient. ...
Colibri Heart Valve LLC, a privately held emerging medical device company, today announced that the first two patients have been successfully enrolled in a clinical early feasibility study (EFS) of the company’s disruptive second-generation ready-for-use balloon-expandable transcatheter aortic valve implantation (TAVI) system. As with ...
Colibri Heart Valve, LLC, a privately held medical device company, has been granted yet another patent directed to prosthetic heart valves. More particularly, today the U.S. Patent & Trademark Office granted Colibri U.S. Patent No. 8,361,144 entitled, “Percutaneously Deliverable Heart Valve Device And Methods Associated Therewith.” The patent is directed to a method of making a ...
“The Colibri TAVI System is designed to address the expanding patient populations including those in the emerging markets which the company is preparing to pursue globally through our Chinese joint venture, Venibri Medtech.” A crimped and loaded heart valve on a delivery catheter which is pre-packaged and ready-for-use, provides significant time, ...
” A pre-packaged, ready-for-use, THV System provides significant time and cost benefits associated with a transcatheter heart valve replacement procedure and is ideally suited for expanding the use of this treatment modality into emerging world markets. With the strengthened patent portfolio, Colibri is positioned to advance clinical ...
Colibri Heart Valve LLC, a privately held emerging medical device company focused on structural heart applications, announces the formation of a new company called Colorado Therapeutics LLC. ...
Colibri Heart Valve LLC, a privately held emerging medical device company focused on structural heart applications, announces the formation of a new company called Colorado Therapeutics LLC. ...
Patent No. 9,125,739 (the “’739 Patent”) titled, “Percutaneous Replacement Heart Valve and a Delivery and Implantation System.” This will be Colibri’s 12th allowed/granted patent and will issue on September 8, 2015. ...